High-Flow Tracheal Oxygen During Spontaneous Breathing Trial (HFTO-SBT)

November 16, 2026 updated by: Gustavo Plotnikow, Argentinian Intensive Care Society

Effect of High-flow Tracheal Oxygen on End-expiratory Lung Impedance and Work of Breathing in Intubated Patients During a Spontaneous Breathing Trial.

The purpose of this study is to find out whether high-flow tracheal oxygen (HFTO) delivered at flows greater than 60 L/min can increase end-expiratory lung volume (EELV) in intubated patients during a spontaneous breathing trial (SBT).

Weaning from mechanical ventilation can be difficult, especially in patients at higher risk of failure. During an SBT, losing positive end-expiratory pressure (PEEP) can cause the lungs to lose volume and make breathing harder by increasing the work of breathing (WOB). HFTO may help reduce the work of breathing, but previous studies using flows of 30-60 L/min did not consistently show an increase in EELV. Higher flows may create more airway pressure.

Therefore, the main question this study is trying to answer is: In intubated patients during an SBT, does HFTO at flows greater than 60 L/min increase EELV? The hypothesis is that HFTO at flows above 60 L/min will increase EELV during the SBT.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Buenos Aires, Argentina, 1280AEB
        • Recruiting
        • Hospital Británico de Buenos Aires
        • Contact:
          • Gustavo Adrián Plotnikow, PhD, Head of Department
          • Phone Number: +54 9 11 6454 3771
          • Email: gplotnikow@gmail.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age ≥ 18 years
  • Invasive mechanical ventilation ≥ 24 hours
  • Presence of esophageal balloon catheter
  • Meets criteria to start an SBT
  • Signed informed consent by patient or responsible family member

Exclusion Criteria:

  • Neuromuscular or neurodegenerative disease
  • contraindication to electrical impedance tomography (e.g., implantable defibrillator)
  • Impossible to place EIT electrode belt (e.g., wound dressings or chest drains)

Elimination Criteria:

  • Flow intolerance
  • Behavioral/cognitive alterations that interrupt measurements in two consecutive attempts.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Sequence A (HFTO 50 → HFTO 70)

Participants randomized to this Sequence receive the following conditions during a spontaneous breathing trial (SBT):

T-piece (baseline) - 15 minutes

High-flow tracheal oxygen (HFTO) at 50 L/min - 15 minutes

Washout on T-piece - 15 minutes

HFTO at 70 L/min - 15 minutes

Washout on T-piece - 15 minutes

Pressure support ventilation (PSV) 7 cmH₂O / PEEP 0 cmH₂O - 15 minutes

Throughout the sequence, end-expiratory lung impedance (EELI), work of breathing (esophageal pressure-derived parameters), respiratory rate, SpO₂, hemodynamic variables, dyspnea, and diaphragmatic thickening fraction (DTF) are measured. This is one of two randomized crossover sequences; all participants receive all conditions in the order assigned by randomization.

Experimental: Sequence B (HFTO 70 → HFTO 50)

Participants randomized to this Sequence receive the following conditions during a spontaneous breathing trial (SBT):

T-piece (baseline) - 15 minutes

High-flow tracheal oxygen (HFTO) at 70 L/min - 15 minutes

Washout on T-piece - 15 minutes

HFTO at 50 L/min - 15 minutes

Washout on T-piece - 15 minutes

Pressure support ventilation (PSV) 7 cmH₂O / PEEP 0 cmH₂O - 15 minutes

Throughout the sequence, end-expiratory lung impedance (EELI), work of breathing (esophageal pressure-derived parameters: ΔPes, PTPes, PTPes-min), respiratory rate, SpO₂, hemodynamic variables, dyspnea, and diaphragmatic thickening fraction (DTF) are measured. This is one of two randomized crossover sequences; all participants receive all conditions in the order assigned by randomization.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in end-expiratory lung impedance (EELI) during spontaneous breathing trial
Time Frame: Baseline (t0, T-piece); after 15 minutes of HFTO 50 L/min; after 15 minutes of HFTO 70 L/min; after 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with 15 minutes T-piece washout periods between conditions.

Change in global end-expiratory lung impedance (ΔEELI; arbitrary units), measured by electrical impedance tomography (EIT), expressed as tidal variation of the first stable respiratory cycle, among four conditions in intubated adult patients during a spontaneous breathing trial: T-piece, high-flow tracheal oxygen (HFTO) at 50 L/min, HFTO at 70 L/min, and pressure support ventilation (PSV) 7 cmH₂O / PEEP 0 cmH₂O. Because this is a randomized crossover study, the primary comparison is within-subject across conditions.

Baseline (t0, T-piece); after 15 minutes of HFTO 50 L/min; after 15 minutes of HFTO 70 L/min; after 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with 15 minutes T-piece washout periods between conditions.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in esophageal pressure swing
Time Frame: Baseline (t0, T-piece); after 15 minutes of HFTO 50 L/min; after 15 minutes of HFTO 70 L/min; after 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with 15 minutes T-piece washout periods between conditions.

Change in esophageal pressure swing (ΔPes; units cmH2O) across conditions (T-piece, HFTO 50 L/min, HFTO 70 L/min, PSV 7 cmH₂O / PEEP 0 cmH₂O).

Baseline (t0, T-piece); after 15 minutes of HFTO 50 L/min; after 15 minutes of HFTO 70 L/min; after 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with 15 minutes T-piece washout periods between conditions.
Change in Diaphragmatic Thickening Fraction (DTF)
Time Frame: Baseline (t0, T-piece); at the end of 15 minutes of HFTO 50 L/min; at the end of 15 minutes of HFTO 70 L/min; at the end of 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with 15 minutes T-piece washout periods between conditions.

Change in diaphragmatic thickening fraction (DTF; Units percentage) measured by ultrasonography, calculated as:

DTF = [(thickness at end-inspiration - thickness at end-expiration) / thickness at end-expiration] × 100.

Baseline (t0, T-piece); at the end of 15 minutes of HFTO 50 L/min; at the end of 15 minutes of HFTO 70 L/min; at the end of 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with 15 minutes T-piece washout periods between conditions.
Respiratory rate
Time Frame: Baseline (t0, T-piece); after 15 minutes of HFTO 50 L/min; after 15 minutes of HFTO 70 L/min; after 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with T-piece washout periods between conditions.

Number of ventilatory cicles per minute

Baseline (t0, T-piece); after 15 minutes of HFTO 50 L/min; after 15 minutes of HFTO 70 L/min; after 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with T-piece washout periods between conditions.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Days of invasive mechanical ventilation to weaning
Time Frame: Baseline

Days of invasive mechanical ventilation from the intubation to the first weaning attempt

Baseline
ICU length of stay
Time Frame: From ICU admission through ICU discharge or death, assessed up to [28 days] after enrollment/randomization.

Duration of stay in the intensive care unit (ICU) from ICU admission to ICU discharge or death, whichever occurs first (Units; days)

From ICU admission through ICU discharge or death, assessed up to [28 days] after enrollment/randomization.
ICU mortality
Time Frame: Through ICU discharge or up to [28 days] after enrollment/randomization.

Number of participants who died in the ICU.

Through ICU discharge or up to [28 days] after enrollment/randomization.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

March 31, 2027

Study Registration Dates

First Submitted

September 29, 2026

First Submitted That Met QC Criteria

October 2, 2026

First Posted (Actual)

October 7, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe